Enlicitide, an Investigational Oral PCSK9 Inhibitor, Demonstrated Significantly Greater LDL-C Reductions Compared to Oral Non ...

Q. I am an 81-year-old woman in excellent health. The only thing that might be worrisome is LDL cholesterol of 181. I ...

A recent randomized clinical trial has demonstrated that targeting a low-density lipoprotein (LDL) cholesterol level of less ...

March 30 () - Merck's oral drug reduced bad cholesterol by up to ‌64.6% in a late-stage trial, ‌the drugmaker said on Monday, ...

Using cholesterol-lowering medications more intensively to achieve a more aggressive target for low-density lipoprotein cholesterol (LDL-C) reduced the rate of major cardiovascular events by one-third ...

Highlights from dyslipidemia research presented at the American College of Cardiology Scientific Sessions 2026, focusing on ...

Merck is eyeing a quick review for its lipid-lowering drug candidate enlicitide, which in December was awarded a Commissioner ...

A study was conducted to determine the association between TG/HDL-C ratio and risk for CVD in patients with HIV.

In another study of dyslipidemic patients not treated with hypolipidemic drugs (baseline examination), a very good correlation between LDL-C and apoB (r = 0.903; p < 0.001) was found. [66] In spite of ...

In patients with cardiovascular disease or who are at high risk for CVD, lerodalcibep significantly decreases LDL-C. Lerodalcibep significantly decreases low-density lipoprotein cholesterol (LDL-C) in ...

In a traditional observational analysis, associations of LDL-C with incident chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and all-cause mortality were U-shaped or ...